Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
11 drugs in development
By Therapeutic Area
top 5
R&D Momentum
89/100
Pipeline Velocity
69/100
Trial Completion Rate
72/100
Pipeline Concentration
44/100
Pipeline Freshness
61/100
Strategic Signals
Activity
Last 14 days
Mapping of Human Cognition
Developing Biomarker-Supported SSD Prevention
Inhaled Nitric Oxide (iNO) for Congenital Diaphragmatic Hernia (CDH) - The "NoNO Trial" - a Multi-center, De-implementation, Stepped-wedge, Cluster-randomized Trial Within an Established Collaborative
Patient Priorities Aligned Discrete Decision Making for Older Adults With Multiple Chronic Conditions.
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)